August J. Troendle, chief executive officer of Medpace Holdings, Inc., sold 17,610 shares of $MEDP common stock on August 11, 2026. The open-market sale executed at $605.11 per share and totaled $10,655,987.10, according to the Form 4 filed with the SEC on August 12, one day after the trade. After the transaction, Troendle held 615,802 shares.
The August 11 sale followed a smaller sale the previous trading day. On August 10, Troendle sold 5,534 shares at $601.53 per share for $3,328,867.02. Both transactions were reported in the same August 12 filing, with the August 10 trade carrying a two-day disclosure lag.
Combined, the two August sales totaled $13,984,854.12 across 23,144 shares. The August 10 sale left Troendle with 633,412 shares; the August 11 sale reduced that figure to 615,802 shares.
The two August sales extended a sequence of open-market sales by Troendle recorded in the database across late 2025. In November 2025, he reported sales that included 59,025 shares at $607.78 on November 24 for $35,874,214.50, 42,392 shares at $615.52 on November 25 for $26,093,123.84, and 41,331 shares at $606.88 on November 26 for $25,082,957.28. Each of those November sales was open-market.
In early December 2025, Troendle sold 23,178 shares at $593.25 on December 1 for $13,750,348.50, 5,698 shares at $590.47 on December 2 for $3,364,498.06, and 668 shares at $590.69 on December 3 for $394,580.92. The December 1 sale was the largest of that three-day stretch, and those sales were reported in filings dated December 3 and December 4.
Earlier in 2025, Troendle reported open-market sales on August 29 of 36,196 shares at $475.90 for $17,225,676.40, and on September 2 of 1,197 shares at $475.11 for $568,706.67.
The August filing window also included activity from another Medpace insider. Director Cornelius P. McCarthy III sold 795 shares of $MEDP on August 7 at $585.071 per share, a transaction totaling $465,131.45, in a Form 4 filed four days later on August 11.
Separately, congressional records show Representative David J. Taylor disclosed a $MEDP purchase on May 15, 2026, with a reported midpoint value of $1,001. Congressional dollar figures are midpoint estimates of the bracketed ranges shown on STOCK Act disclosures.
Across the reported transactions, Troendle's post-trade holdings moved from 961,995 shares after the August 27, 2025 sale to 615,802 shares after the August 11, 2026 sale.